AUGUST – OCTOBER 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA August 22 – Amivantamab – NSCLC EGFR. The European Commission (EC) has approved an extension of indication for the anti-EGFR-MET bispecific antibody in combination with carboplatin and pemetrexed, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R […]